Clinical Trials

Text Size A A

E-Mail to a Friend






secret  Click to Play Audio


Multiple Myeloma

 

Carfilzomib + Melphalan/Prednisone for Newly Diagnosed Multiple Myeloma (CLARION Study)
A Randomized, Open-label Phase 3 Study of Carfilzomib, Melphalan, and Prednisone Versus Bortezomib, Melphalan, and Prednisone in Transplant-ineligible Patients With Newly Diagnosed Multiple Myeloma

Investigator: Edward Libby, MD;   Conditions: Multiple Myeloma;    Status: Recruiting;   Study ID: NCT01818752

Yttrium Y 90 anti-CD45 monoclonal antibody BC8 + Chemo + TDI before Transplant for Multiple Myeloma (2450)
A Phase I Study of 90Y-BC8-DOTA monoclonal antibody, Fludarabine and TBI Followed by HLA-Matched, Allogeneic Peripheral Blood Stem Cell Transplant for the Treatment of Multiple Myeloma

Investigator: Bill Bensinger, MD;   Conditions: Refractory Multiple Myeloma, Stage I Multiple Myeloma, Stage II Multiple Myeloma, Stage III Multiple Myeloma;    Status: Recruiting;   Study ID: NCT01503242

Lenalidomide + Bortezomib + Dexamethasone for Multiple Myeloma (2477)
A Randomized Phase III Study Comparing Conventional Dose Treatment Using a Combination of Lenalidomide, Bortezomib and Dexamethasone (RVD) to High-Dose Treatment with Peripheral Stem Cell Transplant in the Initial Management of Myeloma in Patients up to 65 Years of Age (IFM/DFCI 2009)

Investigator: Bill Bensinger, MD;   Conditions: Multiple Myeloma;    Status: Recruiting;   Study ID: NCT01208662

Oprozomib, Lenalidomide, and Dexamethasone for Newly Diagnosed Multiple Myeloma (2723)
Phase 1b/2, Multicenter, Open-label Study of Oprozomib, Lenalidomide, and Dexamethasone in Patients with Newly Diagnosed Multiple Myeloma

Investigator: Bill Bensinger, MD;   Conditions: Multiple Myeloma;    Status: Recruiting;   Study ID: NCT01881789

SAR650984 for CD38+ Hematological Malignancies
Dose Escalation Safety and Pharmacokinetic Study of Multiple Intravenous Administrations of a Humanized Monoclonal Antibody (SAR650984) Against CD38 In Patients With Selected CD38+ Hematological Malignancies

Investigator: William Bensinger, MD;   Conditions: Hematological Malignancies;    Status: Recruiting;   Study ID: NCT01084252